•  

    MABXIENCE

    We produce biosimilars with the highest quality standards, in compliance with the requirements of the European Medicines Agency (EMA).

     

  •  

    MABXIENCE

    We produce biosimilars with the highest quality standards, in compliance with the requirements of the European Medicines Agency (EMA).

     

  •  

    MABXIENCE

    We produce biosimilars with the highest quality standards, in compliance with the requirements of the European Medicines Agency (EMA).

     

  •  

    MABXIENCE

    We produce biosimilars with the highest quality standards, in compliance with the requirements of the European Medicines Agency (EMA).

     

 

One step ahead in biotechnology

mAbxience is a Chemo company specializing in the development and production of biologicals. It has two manufacturing facilities for active pharmaceutical ingredients: one in Buenos Aires, Argentina; and the other in León, Spain. Both plants have single-use bioreactors, a world-leading technology to ensure the purity and quality of medicines under the highest international quality standards. The development and production of monoclonal antibodies is supplemented with a partnership for the formulation and fractioning of these products with laboratory Sinergium Biotech.

Sinergium Biotech has the first plant in Argentina for the production of vaccines and biotechnologicals. The scientific and technological complex is located in Garín, Buenos Aires Province, and its integrated productive capacity reaches 30 million doses per year. The plant meets international Good Manufacturing Practices (GMP), in compliance with US Food and Drug Administration (FDA) and European Medicines Agency (EMA) requirements.

Our products include biosimilar monoclonal antibodies used for the treatment of various cancer types, and autoimmune diseases such as rheumatoid arthritis, in addition to several recombinant proteins. Thus, biosimilars contribute to reduce the cost of biotechnologicals and expand access of patients to treatment for severe conditions.

These medicines are developed using the biosimilarity by design technology, which enables obtaining a biosimilar that is indistinguishable from the market reference product, also termed fingerprint-like similarity.

 

+ Read more

News Mabxience

BIO San Diego Fair: Grupo Insud announced investments in biotechnology for more than 80 million dollars in Argentina

The international biotechnology fair held this month in San Diego, USA, is the most important in the world and seeks to help develop the global biotechnology industry. Local officials traveled there, from where they made some announcements. The first one … Continue reading

+
(Español) 26-6-2017 Del Fuego Noticias

Anticuerpos monoclonales de Mabxience

Monoclonal antibodies are a type of therapy that in recent years has gained great interest in the effective response it offers to different difficult to treat diseases. The human body constantly generates antibodies, and these are the ones that allow … Continue reading

+